In particular, B cell depletion with the anti-CD20 antibody rituximab seems to work for RA patients resistant to standard disease-modifying antirheumatic drugs (DMARDs) and tumor necrosis factor ...

Background: Widespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world ...

However, she reckons it will still trail Roche's first-to-market anti-CD20 drug Ocrevus (ocrelizumab), even though that drug needs to be administered by intravenous infusion. While it requires a ...

The traditional principles of the treatment of RA are empirical. The use of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) for the control of pain and inflammation is combined with ...

and will enter an increasingly competitive market in which Roche has been setting the pace recently with Ocrevus (ocrelizumab), an anti-CD20 drug which has already become a blockbuster following ...

Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...

LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

and includes discussion of the drug's potential role in novel therapeutic protocols. Rituximab, a monoclonal antibody directed against CD20, has been successfully used in hematological B-cell ...

LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras ... The Bruton tyrosine kinase inhibitor acalabrutinib (Calquence; AstraZeneca) was approved for use with ...